10-Q: Owlet Inc. Reports Strong Revenue Growth in Q3 2024, Secures New Financing

Owlet Inc. saw a significant increase in revenue during the third quarter of 2024, alongside securing new debt and equity financing to support its operations.

Summary

• Owlet Inc. experienced a substantial revenue increase of 140.9% in the third quarter of 2024, reaching $22.1 million, compared to $9.2 million in the same period last year.
• The company's gross profit also saw a significant jump, increasing by 246.8% to $11.5 million.
• For the nine months ended September 30, 2024, revenue increased by 74.4% to $57.6 million compared to $33.0 million in the same period of 2023.
• The company secured a new term loan facility of up to $15 million with WTI and an asset-based revolving credit facility of up to $15 million with ABL OPCO LLC.
• Owlet issued 3,135,136 shares of common stock at $3.70 per share, generating net proceeds of $10.6 million.
• The company also issued 750,000 shares of redeemable common stock to WTI as part of the loan agreement.
• A private placement in February 2024 resulted in the issuance of 9,250 shares of Series B convertible preferred stock and warrants for $9.3 million.
• The company reported a net loss of $5.6 million for the quarter and $3.5 million for the nine-month period.
• Owlet's cash and cash equivalents stood at $21.5 million as of September 30, 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there is strong revenue growth and new financing, the company is still operating at a loss and has identified material weaknesses in its internal controls. The going concern risk also tempers the positive aspects.

Positives

• Owlet experienced a significant increase in revenue and gross profit, indicating strong demand for its products.
• The company successfully secured new debt and equity financing, improving its financial position.
• Gross margin improved significantly, suggesting better cost management and pricing strategies.
• The company regained compliance with the NYSE's continued listing standards.
• The company has taken steps to enhance the design of controls to remediate material weaknesses related to sales returns, accrued sales tax, and convertible preferred stock and warrant arrangements.

Negatives

• The company reported a net loss of $5.6 million for the quarter and $3.5 million for the nine-month period.
• Owlet identified material weaknesses in its internal control over financial reporting.
• The company has a history of operating losses and negative cash flows, raising concerns about its ability to continue as a going concern.
• The company recognized a $1.873 million impairment charge related to an internally developed software project.
• The company's borrowing base availability under the ABL Line of Credit was only $673,000 as of September 30, 2024.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring operating losses and negative cash flows.
• Owlet faces risks related to regulatory approvals and certifications for its products in various jurisdictions.
• The company is involved in ongoing legal proceedings, including class action lawsuits, which could have a material adverse effect on its business.
• The company relies on a limited number of retailers for a substantial portion of its sales.
• The company has identified material weaknesses in its internal control over financial reporting, which could lead to misstatements in its financial statements.
• The company may need to raise additional capital in the future, which may not be available on acceptable terms or at all.

Future Outlook

The company's future performance is subject to various risks and uncertainties, including its ability to maintain regulatory approvals, manage its growth, and secure additional financing. The company is focused on expanding its product offerings and distribution channels, but there is no guarantee of success.

Management Comments

• The converting holders of Series A Preferred Stock communicated to the Company that the election to convert a portion of shares of Series A Preferred Stock was due to the continued positive progress of the Company's business and operating results, an initial step in simplifying the Company's capital structure, and part of a coordinated effort by the Company to help ensure it regained compliance with the global market capitalization requirement under the NYSE Listed Company Manual.

Industry Context

The company operates in the competitive market of baby monitoring and health technology. The increased revenue suggests a growing demand for its products, but the company faces challenges in maintaining profitability and navigating regulatory hurdles. The company's focus on digital parenting platforms aligns with the broader trend of connected health devices.

Comparison to Industry Standards

• Owlet's revenue growth of 140.9% in Q3 2024 significantly exceeds the average growth rate for the consumer health technology sector, which typically sees growth in the range of 10-20% annually. Comparably, companies like Masimo (MASI) and Dexcom (DXCM), which operate in the medical device space, have reported revenue growth in the 15-25% range in recent quarters.
• The company's gross margin of 52.2% in Q3 2024 is competitive with other companies in the consumer health technology space. For example, Fitbit (now part of Google) has historically reported gross margins in the 40-50% range, while companies like Garmin (GRMN) have reported gross margins in the 50-60% range.
• However, Owlet's net loss of $5.6 million in Q3 2024 contrasts with the profitability of more established companies in the sector. For example, Masimo and Dexcom have reported positive net income in recent quarters, indicating a more mature and stable financial position.
• The company's reliance on a limited number of retailers for a substantial portion of its sales is a risk factor that is not typical of larger, more diversified companies in the sector. Companies like Apple (AAPL) and Samsung (SSNLF), which also sell consumer health technology products, have a much broader distribution network.
• The company's recent financing activities, including the issuance of common stock and convertible preferred stock, are common strategies for early-stage companies in the sector. However, the company's need for additional capital raises concerns about its long-term financial sustainability.

Management Changes

Legal Proceedings

• The company is involved in ongoing legal proceedings, including class action lawsuits, which could have a material adverse effect on its business.
• On August 26, 2024 and October 3, 2024, investors filed in the U.S. District Court for the Central District of California, derivatively on behalf of the Company, complaints asserting claims for violations of Section 14(a) of the Exchange Act, as well as state law claims, including breach of fiduciary duty, unjust enrichment and waste of corporate assets.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees may be affected by potential cost reductions or changes in compensation.
• Customers may benefit from the company's continued product development and expansion.
• Suppliers may see increased demand for their products and services.
• Creditors may be impacted by the company's debt obligations and financial performance.

Next Steps

• The company will continue to focus on expanding its product offerings and distribution channels.
• The company will work to remediate the identified material weaknesses in its internal control over financial reporting.
• The company will need to secure additional financing to support its operations and growth.
• The company will need to maintain compliance with the NYSE's continued listing standards.

Key Dates

Keywords

revenue, financing, debt, equity, gross profit, net loss, internal control, medical device, regulatory, Dream Sock, BabySat, stock offering, warrants, convertible preferred stock